Aligos Therapeutics
ALGS · Nasdaq · United States
Share price · ALGS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALGS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-18.1%
Nothing announced by ALGS that day or the session before.
- 16 Nov 2026-21.0%
Nothing announced by ALGS that day or the session before.
- 11 Nov 2026-16.0%
Nothing announced by ALGS that day or the session before.
- 10 Nov 2026-34.9%
Nothing announced by ALGS that day or the session before.
- 6 Nov 2026-9.8%
- 31 Aug 2026-15.2%
Nothing announced by ALGS that day or the session before.
- 10 Aug 2026+36.9%
Nothing announced by ALGS that day or the session before.
- 6 Aug 2026+16.2%
- 3 Aug 2026+8.7%
Nothing announced by ALGS that day or the session before.
- 24 Jul 2026-13.0%
Nothing announced by ALGS that day or the session before.
Share of unusual movement by asset
For each asset, the share of ALGS's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 9% |
| Sessions with no dated event | — | 91% |
No dated announcements about its assets since 3 Sep 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Thyroid hormone receptor-betaSmall molecule | MASH / NASH |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $2.8M | $19M | $32M+ $0 short-term inv. | $22M$1.4M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $24M | $30M+ $0 short-term inv. | $1.5M-$25M operating cash flow | report ↗ |
| 2026-Q1 | $2.8M | $23M | $30M+ $25M short-term inv. | $23M-$23M operating cash flow | report ↗ |
| 2025-Q3 | $0.7M | $24M | $42M+ $57M short-term inv. | $32M-$24M operating cash flow | report ↗ |
| 2025-Q2 | $1.0M | $14M | $19M+ $104M short-term inv. | $16M-$16M operating cash flow | report ↗ |
| 2025-Q1 | $0.3M | $15M | $74M+ $64M short-term inv. | —-$21M operating cash flow | report ↗ |
| 2024-Q3 | $1.3M | $17M | $35M+ $40M short-term inv. | $19M-$20M operating cash flow | report ↗ |
| 2024-Q2 | $1.1M | $21M | $45M+ $49M short-term inv. | —-$19M operating cash flow | report ↗ |
| 2024-Q1 | $0.7M | $16M | $24M+ $89M short-term inv. | $35M-$23M operating cash flow | report ↗ |
| 2023-Q3 | $1.1M | $16M | $71M | $18M-$20M operating cash flow | report ↗ |
| 2023-Q2 | $4.3M | $17M | $91M+ <$0.1M short-term inv. | $19M-$14M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $18M | $79M+ $25M short-term inv. | $23M-$22M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $18M | $87M+ $56M short-term inv. | $19M-$17M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $17M | $71M+ $88M short-term inv. | $20M-$25M operating cash flow | report ↗ |
| 2022-Q1 | — | $32M | $106M+ $79M short-term inv. | $36M-$20M operating cash flow | report ↗ |
| 2021-Q3 | — | $28M | $240M+ $2.5M short-term inv. | $33M-$25M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $2.2M | $69M | $18M+ $60M short-term inv. | $6.0M-$83M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $3.6M | $70M | $37M+ $20M short-term inv. | $33M-$81M operating cash flow | report ↗ |
| 2023-FY | $6.2M | $73M | $136M | $22M-$79M operating cash flow | report ↗ |
| 2022-FY | $0 | $85M | $81M+ $44M short-term inv. | $24M-$79M operating cash flow | report ↗ |
| 2021-FY | $0 | $104M | $187M+ $3.9M short-term inv. | $32M-$116M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-25 | Hirth Peter · director | Award / grant (derivative) | 5,860 | — | — | Form 4 |
| 2026-06-25 | Nuechterlein Carole · director | Award / grant (derivative) | 5,860 | — | — | Form 4 |
| 2026-06-25 | Scopa James Paul · director | Award / grant (derivative) | 5,860 | — | — | Form 4 |
| 2026-06-25 | Martell Bridget A · director | Award / grant (derivative) | 5,860 | — | — | Form 4 |
| 2026-06-25 | Chavez Margarita · director | Award / grant (derivative) | 5,860 | — | — | Form 4 |
| 2026-06-25 | Preston Heather · director | Award / grant (derivative) | 5,860 | — | — | Form 4 |
| 2026-03-09 | BLATT LAWRENCE · director, President and CEO | Award / grant (derivative) | 105,840 | — | — | Form 4 |
| 2026-03-09 | Calhoun Lesley Ann · See Remarks | Award / grant (derivative) | 37,485 | — | — | Form 4 |